

Technology Appraisal Committee Meeting (Committee D)

Minutes: Confirmed

Date and Time: Thursday 17 January 2019 10:00am – 1:21pm

Venue: National Institute for Health and Care Excellence
Level 1A, City Tower
Piccadilly Plaza
Manchester
M1 4BT

Present:	1. Chair, Professor Gary McVeigh	Present for all notes
	2. Vice Chair, Dr Lindsay Smith	Present for all notes
	3. Dr Nabeel Alsindi	Present for all notes
	4. Professor David Bowen	Present for all notes
	5. Gillian Ells	Present for all notes
	6. Professor Paula Ghaneh	Present for notes 6 to 14
	7. Rebecca Harmston	Present for all notes
	8. Dr Andrew Hitchings	Present for all notes
	9. Dr Bernard Khoo	Present for all notes
	10. Dr Soo Fon Lim	Present for all notes
	11. Dr Guy Makin	Present for all notes
	12. Professor David Meads	Present for all notes
	13. Libby Mills	Present for all notes
	14. Olaolu Oloyede	Present for all notes
	15. Dr Paula Parvulescu	Present for all notes

In attendance:

Dr Samreen Ahmed	Clinical Expert nominated by British Thoracic Oncology Group and Royal Collage of Physicians	Present for notes 6 to 14
Rebecca Bouch	Administrator, National Institute for Health and Care Excellence	Present for all notes
Stephanie Callaghan	Project Manager, National Institute for Health and Care Excellence	Present for all notes
Peter Clark	CDF Lead,	Present for all notes

NHS England

Carol Davies	Patient Expert nominated by National Lung Cancer Forum for Nurses	Present for notes 6 to 14
Caron Jones	Technical Advisor, National Institute for Health and Care Excellence	Present for all notes
Helen Knight	Programme Director, National Institute for Health and Care Excellence	Present for all notes
Linda Landells	Associate Director, National Institute for Health and Care Excellence	Present for all notes
Joanne Lord	ERG, Southampton Health Technology Assessments Centre	Present for notes 6 to 14
Jonathan Shepherd	ERG, Southampton Health Technology Assessments Centre	Present for notes 6 to 14
Emily Eaton Turner	Technical Analyst, National Institute for Health and Care Excellence	Present for all notes
Non-public attendees:		
Sarah Bromley	Medical Editor, National Institute for Health and Care Excellence	Present for notes all notes
Merce Obach Cortadellas	Technical Advisor, National Institute for Health and Care Excellence	Present for notes all notes
Abigail Dunne	Management Accountant, National Institute for Health and Care Excellence	Present for notes all notes
Nicole Elliott	Associate Director - Clinical Guidelines Update Programme, National Institute for Health and Care	Present for notes all notes

	Excellence	
Ann Greenwood	Senior Medical Editor, National Institute for Health and Care Excellence	Present for notes all notes
Omar Moreea	Technical Analyst, National Institute for Health and Care Excellence	Present for notes all notes
Maroulla Whitely	Business Analyst - Resource Impact Assessment, National Institute for Health and Care Excellence	Present for notes all notes

Notes

Welcome

1. The Chair welcomed all members of the Committee and other attendees present to the meeting. The Chair reviewed the agenda and timescales for the meeting, which included the appraisals of atezolizumab in combination for treating advanced non-squamous non-small-cell lung cancer.
2. The Chair welcomed Dr Soo Fon Lim and Olaolu Oloyedeto their first meeting as a member of the Appraisal Committee
3. The Chair informed the Committee of the non-public observers at this meeting: Sarah Bromley, Merce Obach Cortadellas, Abigail Dunne, Nicole Elliott, Anne Greenwood, Omar Moreea and Maroulla Whitely
4. Apologies were received from Professor Rachel Elliott, Dr Peter Hall and Dr Malcolm Oswald

Any other Business

5. None

Appraisal of atezolizumab in combination for treating advanced non-squamous non-small-cell lung cancer.

Part 1 – Open session

6. The Chair welcomed the invited experts: Dr Samreen Ahmed, Peter Clark, Carol Davies and Gary Middleton to the meeting and they introduced themselves to the Committee.
7. The Chair welcomed company representatives from Roche to the meeting.
8. The Chair asked all Committee members to declare any relevant interests Dr Lindsay Smith, Dr Nabeel Alsindi, Professor David Bowen, Gillian Ells, Professor Paula Ghaneh, Rebecca Harmston, Dr Andrew Hitchings, Dr Bernard Khoo, Dr

Soo Fon Lim, Dr Guy Makin, Professor David Meads, Libby Mills, Olaolu Oloyede and Dr Paula Parvulescu all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of atezolizumab in combination for treating advanced non-squamous non-small-cell lung cancer.

9. The Chair asked all NICE Staff to declare any relevant interests.
 - 9.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of Atezolizumab in combination for treating advanced non-squamous non-small-cell lung cancer [ID1210].
10. The Chair asked all other invited guests to declare their relevant interests.
 - 10.1. Dr Samreen Ahmed, Peter Clark, Carol Davies, Joanne Lord, Gary Middleton and Jonathan Shepherd all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of atezolizumab in combination for treating advanced non-squamous non-small-cell lung cancer.
 - 10.2. Gary Middleton declared a personal non-direct interest as he has received travel and reimbursement from the Company, Roche.
 - 10.2.1. It was agreed that this declaration would not prevent Gary Middleton from participating in this section of the meeting
 - 10.3. Dr Samreen Ahmed declared a personal non-direct interest as she has been on the advisory committee board for Roche.
 - 10.3.1. It was agreed that this declaration would not prevent Dr Samreen Ahmed from participating in this section of the meeting
11. The Chair introduced the lead team, Dr Nabeel Alsindi, Rebecca Harmston and Dr Paula Parvulescu who gave presentations on the clinical effectiveness and cost effectiveness of atezolizumab in combination for treating advanced non-squamous non-small-cell lung cancer.
12. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.
13. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.
14. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

15. Discussion on confidential information continued. This information was supplied by the company.
16. The Committee continued to discuss the clinical and cost effectiveness of Atezolizumab in combination for treating advanced non-squamous non-small-cell lung cancer [ID1210].
 - 16.1. The committee decision was based on consensus.
17. The Committee instructed the technical team to prepare the Appraisal Consultation Document (ACD) in line with their decisions.

Date, time and venue of the next meeting

18. Thursday 14 February 2019 10:00-17:00 at National Institute for Health and Care Excellence, Level 1A, City Tower, Piccadilly Plaza, Manchester M1 4BT.